39
Participants
Start Date
September 18, 2019
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
Busulfan 3.2 mg/kg/day
Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
Fludarabine
Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
Melphalan
Melphalan (70mg/m2/day) administered on days -6 and -5.
Antithymocyte globulin (ATG)
ATG will be given based on a dynamic nomogram based on the patient's absolute lymphocyte count at the start of conditioning and can result in 2 or 3 days of ATG administration.
Busulfan 0.8 mg/kg
Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
Allogeneic hematopoietic cell transplantation (Allo-HCT)
Allogeneic hematopoietic cell transplantation following the conditioning regimen.
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center
OTHER